Regulatory
Matters |
|
Bufexamac |
|
Drospirenone-containing
combined oral contraceptive. |
|
Irinotecan. |
|
Naltrexone
for extended-release injectable suspension |
|
Oral
tacrolimus |
|
Parenteral
amphotericin B |
|
Parenteral
amphotericin B |
|
Promethazine
hydrochloride injection |
|
Propylthiouracil |
|
Rivastigmine
transdermal patch |
|
Saquinavir
mesilate |
|
Simvastatin
|
|
Zoledronic
acid |
Safety of Medicines |
|
Antidepressants |
|
Carbapenems |
|
Clopidogrel
and proton-pump inhibitors |
|
Eltrombopag
|
|
Entacapone/carbidopa/levodopa
|
|
Gonadotropin-Releasing
Hormone Agonists |
|
H1N1
pandemic vaccines and antiviral |
|
Leflunomide |
|
Natalizumab.
|
|
SSRIs
and SNRIs |
Feature
|
|
WHO
Prequalification of Medicines Programme |
|
Workshop
on Pharmacovigilance Systems in West Africa |